Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

River-52: A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

Cristina Papayannidis, Krzysztof Mądry, Piotr Centkowski, Witold Prejzner, Aleksandra Butrym, Dominik Chraniuk, Chadi Saba, Noemi Angelosanto, Ruth Curley, Hendrik Nogai, Renata Dudziak, Oleksandr Moybenko, Tomasz Rzymski, Milena Mazan, Agnieszka Sroka-Porada, Gary Wilkinson, Eytan M. Stein

Blood (2024) 144 (Supplement 1): 6005.

https://doi.org/10.1182/blood-2024-206906

Published: 2024

Journal Articles

River-81: A Multicenter, Open-Label, Dose-Finding Clinical Trial to Assess Safety, PK, PD, Clinical Efficacy of RVU120 in Combination with Venetoclax in Patients with AML Failing Prior Venetoclax Plus Hypomethylating Agent Therapy

Blood (2024) 144 (Supplement 1): 5999.

https://doi.org/10.1182/blood-2024-200055

Published: 2024

Journal Articles

Trial in Progress: An Open-Label Clinical Trial of RVU120 As Monotherapy and in Combination with Ruxolitinib in Patients with Intermediate or High-Risk, Primary or Secondary Myelofibrosis (POTAMI-61)

Rostislav Kuklík, Adam Falkowski, Zachary Zaroogian, Milena Mazan, Agnieszka Szymula, Gary Wilkinson, Elżbieta Adamczyk, Jerzy Woźnicki, Marta Micek, Diego Coelho, Katarzyna Wiklik, Daniel Grzywczak, Hendrik Nogai, Tomasz Rzymski, Raajit Rampal

Blood (2024) 144 (Supplement 1): 6632.

https://doi.org/10.1182/blood-2024-204897

Published: 2024

Journal Articles

Novel Clinically Useful Inhibitor of Mediator Complex, RVU120, Relives Differentiation Block in MDS/AML

Blood (2023) 142 (Supplement 1): 3225.

https://doi.org/10.1182/blood-2023-186227

Published: 2023

Journal Articles

Preclinical and Clinical Evidence for Erythroid-Stimulating Activity of RVU120 CDK8/19 Inhibitor in AML and MDS

Noemi Angelosanto, Ewa Lech Marańda, Jan Maciej Zaucha, Camille N. Abboud, Agnieszka Sroka-Porada, Wiktoria Ogrodzińska, Magdalena Kozakowska, Urszula Głowniak-Kwitek, Karolina Bukowska-Strakova, Tomasz Rzymski, Milena Mazan, Urszula Pakulska, Kristina Göller, Ewa Zarzycka, Hendrik Nogai

Blood (2023) 142 (Supplement 1): 2800.

https://doi.org/10.1182/blood-2023-189064

Published: 2023

Journal Articles

Targeting CDK8/CDK19 to Disrupt Leukemic Stem Cell-like Population in Acute Myeloid Leukemia: Exploring RVU120 As a Promising Frontline Therapy

Milena Mazan, Urszula Pakulska, Adrianna Moszyńska, Agnieszka Sroka-Porada, Krzysztof Tomasz Szade, Michał Mikula, Magdalena Kozakowska, Przemysław Juszczyński, Katarzyna Wiklik, Kristina Göller, Marta Obacz, Camille N. Abboud, Jan Maciej Zaucha, Ewa Lech Marańda, Noemi Angelosanto, Hendrik Nogai, Tomasz Rzymski

Blood (2023) 142 (Supplement 1): 4175.

https://doi.org/10.1182/blood-2023-188866

Published: 2023

Journal Articles

Multiomics Analysis Confirms Effective Target Engagement for RVU120 - a First-in-Class CDK8/19 Kinase Inhibitor in AML and MR-MDS Patients and Reveals the Mechanism of Action

Blood (2022) 140 (Supplement 1): 5939–5940.

https://doi.org/10.1182/blood-2022-168906

Published: 2022

Journal Articles

SEL24/MEN1703 Inhibits PIM/FLT3 Downstream Target in Acute Myeloid Leukemia (AML) Patients: Results of the Pharmacodynamics (PD) Assay and Genomic Profiling in the First-in-Human Diamond-01 Trial

Blood (2021) 138 (Supplement 1): 3436.

https://doi.org/10.1182/blood-2021-150277

Published: 2021

Journal Articles

Preclinical and Clinical Signs of Efficacy of RVU120 (SEL120), a Specific CDK8/19 Inhibitor in DNMT3A-Mutated AML

Blood (2021) 138 (Supplement 1): 2371.

https://doi.org/10.1182/blood-2021-152273

Published: 2021

Journal Articles

RVU120 (SEL120) CDK8/19 Inhibitor - a Drug Candidate for the Treatment of MDS Can Induce Erythroid Differentiation

Blood (2021) 138 (Supplement 1): 1518.

https://doi.org/10.1182/blood-2021-150662

Published: 2021

Journal Articles

SEL24/MEN1703 Provides PIM/FLT3 Downstream Pathway Inhibition in Acute Myeloid Leukemia (AML) Blast Cells: Results of the Pharmacodynamics (PD) Assay in the Dose Escalation Part of First-in-Human Diamond Trial

Andrea Massimiliano Tomirotti, PhD, Daniela Bellarosa, Scott R. Solomon, MD, Aziz Nazha, MD, Stephen A Strickland, MD MSCI, Roland P Walter, MDPhD, Farhad Ravandi, MBBS, Krzysztof Brzózka, PhD, Milena Mazan, PhD, Simone Baldini, MD, Massimiliano Salerno, Monica Binaschi, PhD, Dirk Laurent, MD, Andrea Pellacani, PhD MD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136936

Published: 2020

Journal Articles

Setbp1 Overexpression Acts in the Place of Class-Defining Somatic Mutations to Drive Mouse and Human FLT3-ITD -Mutant AMLs

Suruchi Pacharne, Oliver M. Dovey, PhD, Jonathan L Cooper, Muxin Gu, Vijay Baskar, PhD, Mathias J Friedrich, Malgorzata Gozdecka, PhD, Sandeep S Rajan, PhD, Etienne De Braekeleer, PhD MSc, Maxim Barenboim, Grace Collord, Hannes Postingl, PhD, Ruben Bautista, Milena Mazan, PhD, Roland Rad, Prof., MD, Konstantinos Tzelepis, Penny Wright, George S. Vassiliou, MD PhD FRCPath, MRCP

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-141743

Published: 2020

Journal Articles

Genetic Vulnerabilities of DNMT3A R882H in Myeloid Malignancies

Malgorzata Gozdecka, PhD, Monika Dudek, MSc, Konstantinos Tzelepis, Aristi Damaskou, MSc, Vijay Baskar, PhD, Penny Wright, Graham Duddy, Eshwar Meduri, PhD, Milena Mazan, PhD, Kosuke Yusa, PhD, Brian J. P. Huntly, PhD MRCP, MB, FRCPath, George S. Vassiliou, FRCPath, MRCP, PhD

Blood (2019) 134 (Supplement_1): 111.

https://doi.org/10.1182/blood-2019-126505

Published: 2019

Journal Articles

CDK8 Inhibitors Induce Transcriptional Reprogramming of AML Cells Associated with Differentiation

Milena Mazan, PhD, Marion Chapellier, PhD, Marcus Järås, PhD, Michal Mikula, MD PhD, Eliza Majewska, PhD, Katarzyna Wiklik, PhD, Michal Combik, PhD, Aniela Golas, PhD, Magdalena Masiejczyk, MSc, Elzbieta Fiedor, MSc, Federico Malusa, MSc, Przemyslaw Juszczynski, Prof., MD PhD, Magdalena Cybulska, DVM, Maciej Mikulski, PhD, Jerzy Ostrowski, Prof., MD PhD, Pawel Chrom, MD PhD, Krzysztof Brzózka, PhD, Tomasz Rzymski, PhD

Blood (2019) 134 (Supplement_1): 3774.

https://doi.org/10.1182/blood-2019-128073

Published: 2019

Journal Articles

Identification of a Pharmacodynamic Biomarker for SEL24/MEN1703, a First-in-Class Dual PIM/FLT3 Kinase Inhibitor for Acute Myeloid Leukemia, and Its Implementation in the First-in-Human Study CLI24-001

Andrea Tomirotti, PhD, Giuseppe Merlino, Alessio Fiascarelli, PhD, Simone Baldini, MD, Alessia Tagliavini, Elisa Borella, Milena Mazan, PhD, Krzysztof Brzózka, PhD, Alessandro Bressan, Andrea Pellacani, PhD MD, Massimiliano Salerno, Monica Binaschi, PhD, Daniela Bellarosa

Blood (2019) 134 (Supplement_1): 5087.

https://doi.org/10.1182/blood-2019-124800

Published: 2019

Journal Articles

SEL120 - a First-in-Class CDK8/19 Inhibitor As a Novel Option for the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome - Data from Preclinical Studies and Introduction to a Phase Ib Clinical Trial

Blood (2019) 134 (Supplement_1): 2651.

https://doi.org/10.1182/blood-2019-127835

Published: 2019

Journal Articles

Small Molecule Screens Identify CDK8-Inhibitors As Candidate Diamond-Blackfan Anemia Drugs

Blood (2018) 132 (Supplement 1): 753.

https://doi.org/10.1182/blood-2018-99-114570

Published: 2018

Journal Articles

CDK8 Inhibitor SEL120-34A Has Therapeutic Efficacy in Murine and Human Acute Myeloid Leukemia Models

Blood (2018) 132 (Supplement 1): 1520.

https://doi.org/10.1182/blood-2018-99-111859

Published: 2018

Journal Articles

Contrasting Stage Dependent Requirements for the Histone Methyltransferase EZH2 during the Evolution of Acute Myeloid Leukemia

Faisal Basheer, MBBChir, MA, George Giotopoulos, PhD, Eshwar Meduri, PhD, Haiyang Yun, PhD, Milena Mazan, PhD, Olivia Sheppard, Daniel Sasca, MD, Malgorzata Gozdecka, PhD, George S. Vassiliou, MD PhD, Brian J.P Huntly

Blood (2017) 130 (Supplement 1): 1215.

https://doi.org/10.1182/blood.V130.Suppl_1.1215.1215

Published: 2017

Journal Articles

GFI1 and GFI1B control the loss of endothelial identity of hemogenic endothelium during hematopoietic commitment

Christophe Lancrin, Milena Mazan, Monika Stefanska, Rahima Patel, Monika Lichtinger, Guilherme Costa, Özge Vargel, Nicola K. Wilson, Tarik Möröy, Constanze Bonifer, Berthold Göttgens, Valerie Kouskoff, Georges Lacaud

Blood (2012) 120 (2): 314–322.

https://doi.org/10.1182/blood-2011-10-386094

Published: 2012

Includes: Multimedia, Supplemental data

NARROW

River-52: A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

River-81: A Multicenter, Open-Label, Dose-Finding Clinical Trial to Assess Safety, PK, PD, Clinical Efficacy of RVU120 in Combination with Venetoclax in Patients with AML Failing Prior Venetoclax Plus Hypomethylating Agent Therapy

Trial in Progress: An Open-Label Clinical Trial of RVU120 As Monotherapy and in Combination with Ruxolitinib in Patients with Intermediate or High-Risk, Primary or Secondary Myelofibrosis (POTAMI-61)

Novel Clinically Useful Inhibitor of Mediator Complex, RVU120, Relives Differentiation Block in MDS/AML

Preclinical and Clinical Evidence for Erythroid-Stimulating Activity of RVU120 CDK8/19 Inhibitor in AML and MDS

Targeting CDK8/CDK19 to Disrupt Leukemic Stem Cell-like Population in Acute Myeloid Leukemia: Exploring RVU120 As a Promising Frontline Therapy

Multiomics Analysis Confirms Effective Target Engagement for RVU120 - a First-in-Class CDK8/19 Kinase Inhibitor in AML and MR-MDS Patients and Reveals the Mechanism of Action

SEL24/MEN1703 Inhibits PIM/FLT3 Downstream Target in Acute Myeloid Leukemia (AML) Patients: Results of the Pharmacodynamics (PD) Assay and Genomic Profiling in the First-in-Human Diamond-01 Trial

Preclinical and Clinical Signs of Efficacy of RVU120 (SEL120), a Specific CDK8/19 Inhibitor in DNMT3A-Mutated AML

RVU120 (SEL120) CDK8/19 Inhibitor - a Drug Candidate for the Treatment of MDS Can Induce Erythroid Differentiation

SEL24/MEN1703 Provides PIM/FLT3 Downstream Pathway Inhibition in Acute Myeloid Leukemia (AML) Blast Cells: Results of the Pharmacodynamics (PD) Assay in the Dose Escalation Part of First-in-Human Diamond Trial

Setbp1 Overexpression Acts in the Place of Class-Defining Somatic Mutations to Drive Mouse and Human FLT3-ITD -Mutant AMLs

Genetic Vulnerabilities of DNMT3A R882H in Myeloid Malignancies

CDK8 Inhibitors Induce Transcriptional Reprogramming of AML Cells Associated with Differentiation

Identification of a Pharmacodynamic Biomarker for SEL24/MEN1703, a First-in-Class Dual PIM/FLT3 Kinase Inhibitor for Acute Myeloid Leukemia, and Its Implementation in the First-in-Human Study CLI24-001

SEL120 - a First-in-Class CDK8/19 Inhibitor As a Novel Option for the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome - Data from Preclinical Studies and Introduction to a Phase Ib Clinical Trial

Small Molecule Screens Identify CDK8-Inhibitors As Candidate Diamond-Blackfan Anemia Drugs

CDK8 Inhibitor SEL120-34A Has Therapeutic Efficacy in Murine and Human Acute Myeloid Leukemia Models

Contrasting Stage Dependent Requirements for the Histone Methyltransferase EZH2 during the Evolution of Acute Myeloid Leukemia

GFI1 and GFI1B control the loss of endothelial identity of hemogenic endothelium during hematopoietic commitment

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only